<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04294004</url>
  </required_header>
  <id_info>
    <org_study_id>KUR-113/01</org_study_id>
    <nct_id>NCT04294004</nct_id>
  </id_info>
  <brief_title>KUR-113 Bone Graft Versus Local Autograft for the Treatment of Single-level Transforaminal Lumbar Interbody Fusion</brief_title>
  <acronym>STRUCTURE</acronym>
  <official_title>A Prospective, Randomized, Controlled, Single-blind, Dose-finding, Multi-center, Parallel Group Study of Safety/Efficacy of KUR-113 Bone Graft Versus Local Autograft for the Treatment of Single-level Transforaminal Lumbar Interbody Fusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kuros Biosurgery AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Factory CRO</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kuros BioSciences B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kuros Biosurgery AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of KUR-113 Bone Graft&#xD;
      (TGplPTH1-34 in fibrin) compared to local autograft for the treatment of Degenerative Disk&#xD;
      Disease (DDD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Degenerative disc disease (DDD) is a common disorder of the lumbar spine. Clinically, DDD&#xD;
      causes discogenic back pain and may cause related radicular, neuropathic, claudicatory, and&#xD;
      referred pain.&#xD;
&#xD;
      This is a prospective, randomized, controlled, single-blind, dose-finding, multi-center study&#xD;
      which intends to demonstrate the safety and efficacy of KUR-113 Bone Graft (TGplPTH1-34 in&#xD;
      fibrin) versus local autograft. The study will enroll 50 patients with Degenerative Disk&#xD;
      Disease (DDD) requiring single-level interbody fusion along with posterolateral fusion (PLF)&#xD;
      with posterior fixation who meet eligibility criteria and agree to participate in the study.&#xD;
      Safety and efficacy of KUR-113 Bone Graft will be evaluated by analyzing all clinical as well&#xD;
      as radiological endpoints and adverse events. This phase 2a study is not powered to detect&#xD;
      non-inferiority. All patients will undergo clinical and radiological assessments at initial&#xD;
      hospital discharge (on average 3 days post-surgery), 6 weeks, 3, 6, 12 and 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Due to the different technical procedures between the control and the intervention arms (KUR-113 Bone Graft versus local autograft), investigators cannot be blinded to the treatment. However, all patients will remain blinded for the duration of their participation in the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Radiographic interbody fusion</measure>
    <time_frame>Month 12 post-surgery</time_frame>
    <description>Evidence of bridging trabeculae or continuous bony connection between superior and inferior vertebral body on CT-scan as determined by an independent radiology expert panel (IREP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint</measure>
    <time_frame>Month 6 and Month 12 post-surgery</time_frame>
    <description>Radiographic interbody fusion using CT-scans, functional outcome (decrease of 15 points or more on Oswestry Disability Index (ODI)) and no post-surgical intervention to aid fusion or replace any of the spinal implants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic interbody fusion</measure>
    <time_frame>Month 6 post-surgery</time_frame>
    <description>Determined by IREP using CT-scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic posterolateral fusion</measure>
    <time_frame>Month 6 and Month 12 post-surgery</time_frame>
    <description>Determined by IREP using CT-scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ODI</measure>
    <time_frame>Week 6, Month 3, Month 6, Month 12, and Month 24 post-surgery</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leg Pain</measure>
    <time_frame>Initial discharge from hospital (on average 3 days post-surgery), Week 6, Month 3, Month 6, Month 12, and Month 24 post-surgery</time_frame>
    <description>Change from baseline using Visual Analogue Scale (VAS). VAS is scored from 0 to 100 with higher numbers being a worse outcome than a lower number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Back Pain</measure>
    <time_frame>Initial discharge from hospital (on average 3 days post-surgery), Week 6, Month 3, Month 6, Month 12, and Month 24 post-surgery</time_frame>
    <description>Change from baseline using Visual Analogue Scale (VAS). VAS is scored from 0 to 100 with higher numbers being a worse outcome than a lower number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Secondary Interventions</measure>
    <time_frame>Up to Month 24 post-surgery</time_frame>
    <description>Revisions, re-operations, removals, supplemental fixations, or any other procedure that adjusts or in any way removes part of the original implant configuration with or without replacement of the components</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Degenerative Disc Disease</condition>
  <condition>Spinal Fusion</condition>
  <arm_group>
    <arm_group_label>KUR-113, Stage 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During stage 1, subjects randomized to this arm will receive TGplPTH1-34 in fibrin (0.4mg/ml) that will be applied within and around a polyetheretherketone (PEEK) intervertebral cage. The maximum dose that will be applied is 4 mg of TGplPTH1-34 in 10mL KUR-113 Bone Graft.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autologous Bone Graft</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During stage 1 of the study, subjects randomized to this arm will receive local autologous bone graft. In the event of insufficient local autograft, Iliac crest bone graft may be used to supplement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KUR-113, Stage 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During stage 2, subjects will receive TGplPTH1-34 in fibrin that will be applied within and around a PEEK intervertebral cage at a concentration of either 0.2mg/ml or 0.7mg/ml. The concentration received will be selected by the DSMB based on the results of stage 1. The maximum dose that will be applied is either 2 mg or 7 mg of TGplPTH1-34 in 10mL KUR-113 Bone Graft.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>TGplPTH1-34 in fibrin</intervention_name>
    <description>TGplPTH1-34 within a fibrin matrix applied within and around a polyetheretherketone (PEEK) intervertebral cage</description>
    <arm_group_label>KUR-113, Stage 1</arm_group_label>
    <arm_group_label>KUR-113, Stage 2</arm_group_label>
    <other_name>KUR-113</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous Bone Graft</intervention_name>
    <description>Local autograft collected from decompression which may be supplemented with iliac crest bone graft (ICBG) if local autograft is insufficient.</description>
    <arm_group_label>Autologous Bone Graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent by the patient.&#xD;
&#xD;
          2. Male or female patient â‰¥ 25 up to and including 75 years old. Females of childbearing&#xD;
             potential with a negative urine pregnancy test at Screening. Females of childbearing&#xD;
             potential must agree to use acceptable contraception for at least 12 months after&#xD;
             surgery and investigational product placement.&#xD;
&#xD;
          3. Patients with degenerative disc disease with up to grade 1 spondylolisthesis and with&#xD;
             leg pain requiring up to 3 levels of laminectomy/decompression and a single-level&#xD;
             fusion (L2 - S1). DDD is defined by the presence of one or more of the following:&#xD;
&#xD;
               1. instability (angulation â‰¥ 5 degrees or translation â‰¥ 3 mm on flexion/extension&#xD;
                  radiographs),&#xD;
&#xD;
               2. osteophyte formation of facet joints or vertebral endplates,&#xD;
&#xD;
               3. decreased disc height by &gt; 2 mm, but dependent upon the spinal level,&#xD;
&#xD;
               4. scarring/thickening of ligamentum flavum, annulus fibrosis or facet joint&#xD;
                  capsule,&#xD;
&#xD;
               5. disc degeneration and/or herniation,&#xD;
&#xD;
               6. facet degeneration,&#xD;
&#xD;
               7. vacuum phenomenon.&#xD;
&#xD;
          4. Patients with an Oswestry Disability Index (ODI) score â‰¥ 35.&#xD;
&#xD;
          5. Patients with a Visual Analogue Scale (VAS) leg score â‰¥ 40.&#xD;
&#xD;
          6. Failed conservative treatment (physical therapy, bed rest, medications, spinal&#xD;
             injections or transcutaneous electrical nerve stimulation) for a period of 6 months&#xD;
             prior to study enrollment.&#xD;
&#xD;
          7. Patients willing to undergo PK sampling.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with open epiphyseal plates.&#xD;
&#xD;
          2. Patient requiring emergency spinal decompression or spinal fusion.&#xD;
&#xD;
          3. Patients requiring multilevel fusion or expected to need secondary intervention within&#xD;
             one year following surgery.&#xD;
&#xD;
          4. Any prior fusion or attempted fusion at an adjacent level.&#xD;
&#xD;
          5. Any prior fusion or attempted fusion at the index level.&#xD;
&#xD;
          6. Pregnant or breast-feeding women.&#xD;
&#xD;
          7. Known or suspected allergies to any of the components of KUR-113 Bone Graft (e.g.&#xD;
&#xD;
             hypersensitivity to aprotinin).&#xD;
&#xD;
          8. Any prior use of teriparatide or abaloparatide or graft material containing PTH1-34.&#xD;
&#xD;
          9. Patients with hypercalcemic disorders (e.g., primary hyperparathyroidism).&#xD;
&#xD;
         10. Patients with Paget's Disease or unexplained high levels of alkaline phosphatase.&#xD;
&#xD;
         11. Prior radiation therapy involving bone.&#xD;
&#xD;
         12. Medical history or radiographic evidence of a metabolic bone disorder (e.g. Paget's&#xD;
             Disease) or other condition that would negatively impact the healing process.&#xD;
&#xD;
         13. Any medical condition requiring radiotherapy or immunosuppression.&#xD;
&#xD;
         14. History of thyroid autoimmune disease (Hashimoto's thyroiditis, Graves' disease) or&#xD;
             hyperthyroidism.&#xD;
&#xD;
         15. Patients on chronic systemic steroids (i.e. &gt; 14 consecutive days) within 6 months&#xD;
             prior to Screening Visit.&#xD;
&#xD;
         16. Osteopenia (T score &lt; -1.0) or osteoporosis of the spine (T score &lt; -2.5).&#xD;
&#xD;
         17. DDD related to benign or malignant tumor.&#xD;
&#xD;
         18. History or presence of active malignancy.&#xD;
&#xD;
         19. Hereditary disorders predisposing to osteosarcoma.&#xD;
&#xD;
         20. Patients with invasive skin cancer.&#xD;
&#xD;
         21. Evidence of local or systemic infection.&#xD;
&#xD;
         22. Patients with known active COVID-19 disease.&#xD;
&#xD;
         23. Current smokers.&#xD;
&#xD;
         24. Type 1 diabetes (regardless of HbA1c) or Type 2 diabetes with a documented HbA1c &gt;&#xD;
             7.0.&#xD;
&#xD;
         25. Any acute or chronic concurrent medical conditions that in the Investigator's opinion&#xD;
             are a contraindication to the procedure and study participation.&#xD;
&#xD;
         26. Participation in another investigational study within 30 days prior to surgery for&#xD;
             investigational devices, or within the last three months for investigational drugs.&#xD;
             (Note: trials requiring extended follow-up for products that were investigational, but&#xD;
             have since become commercially available, are not considered investigational trials).&#xD;
&#xD;
         27. Known substance abuse, psychiatric disorder or a condition which, in the opinion of&#xD;
             the investigator, may influence the healing or ability to comply with protocol&#xD;
             requirements.&#xD;
&#xD;
         28. Involved in active litigation relating to his/her spinal condition or workers&#xD;
             compensation claimants.&#xD;
&#xD;
         29. BMI greater than 40.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Chi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marion Bertrand</last_name>
    <phone>31 (0)30 7400455</phone>
    <email>marion.bertrand@kurosbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Grzyb</last_name>
    <phone>(774) 454-2737</phone>
    <email>sarah.grzyb@avaniaclinical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0863</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Justin Parker Neurological Institute</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Augusta University Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University-Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana Spine Group</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spine Institute of Louisiana</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University at Buffalo Neurosurgery</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 25, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spinal Fusion</keyword>
  <keyword>Posterolateral Fusion</keyword>
  <keyword>MagnetOs</keyword>
  <keyword>Fibrin-PTH (KUR-113)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

